164 related articles for article (PubMed ID: 22918794)
1. Targeting neuroendocrine tumor: mixing standard options with novel therapies.
Raymond E; Dreyer C; Faivre S
Target Oncol; 2012 Sep; 7(3):151-2. PubMed ID: 22918794
[No Abstract] [Full Text] [Related]
2. Pancreatic neuroendocrine and carcinoid tumors: what's new, what's old, and what's different?
Reidy-Lagunes D; Thornton R
Curr Oncol Rep; 2012 Jun; 14(3):249-56. PubMed ID: 22434313
[TBL] [Abstract][Full Text] [Related]
3. Targeted therapies: Good news for advanced-stage pancreatic neuroendocrine tumors.
Spiegel AM; Libutti SK
Nat Rev Clin Oncol; 2011 May; 8(5):258-9. PubMed ID: 21448150
[No Abstract] [Full Text] [Related]
4. DNA repair enzyme expression and differential response to temozolomide in a patient with both glioblastoma and metastatic pancreatic neuroendocrine tumor.
Bracht LK; Wen P; Meyerhardt JA; Kulke MH; Hornick JL; Redston M; LaFrankie DC; Black PM; Kesari S; Norden A; Drappatz J
J Clin Oncol; 2008 Oct; 26(29):4843-4. PubMed ID: 18779600
[No Abstract] [Full Text] [Related]
5. [Current status and therapeutic strategy for pancreatic neuroendocrine tumors in Japan].
Ito T; Igarashi H; Jensen RT; Takayanagi R
Fukuoka Igaku Zasshi; 2012 Jul; 103(7):131-7. PubMed ID: 22978065
[No Abstract] [Full Text] [Related]
6. Resistance to targeted therapies in pancreatic neuroendocrine tumors (PNETs): molecular basis, preclinical data, and counteracting strategies.
Tijeras-Raballand A; Neuzillet C; Couvelard A; Serova M; de Gramont A; Hammel P; Raymond E; Faivre S
Target Oncol; 2012 Sep; 7(3):173-81. PubMed ID: 22923165
[TBL] [Abstract][Full Text] [Related]
7. Progress in the treatment of neuroendocrine tumors.
Chan JA; Kulke MH
Curr Oncol Rep; 2009 May; 11(3):193-9. PubMed ID: 19336011
[TBL] [Abstract][Full Text] [Related]
8. Use of sunitinib in a 30-year-old woman with pancreatic neuroendocrine tumors associated with Von Hippel-Lindau syndrome.
Wang W; Jiang CY; Wang HW
J Clin Gastroenterol; 2015 Jan; 49(1):89-90. PubMed ID: 24921213
[No Abstract] [Full Text] [Related]
9. Sunitinib for advanced pancreatic neuroendocrine tumors.
Hubner RA; Valle JW
Expert Rev Anticancer Ther; 2011 Dec; 11(12):1817-27. PubMed ID: 22117148
[TBL] [Abstract][Full Text] [Related]
10. Temozolomide-associated myelodysplasia 6 years after treatment of a patient with pancreatic neuroendocrine tumor.
Rashidi A; Sorscher SM
Leuk Lymphoma; 2015; 56(8):2468-9. PubMed ID: 25530344
[No Abstract] [Full Text] [Related]
11. Advances in pancreatic neuroendocrine tumor treatment.
Castellano D; Grande E; Barriuso J
N Engl J Med; 2011 May; 364(19):1872-3; author reply 1873-4. PubMed ID: 21561356
[No Abstract] [Full Text] [Related]
12. New treatments of pancreatic neuroendocrine tumors: why using them? How to use them?
Raymond E; Ruszniewski P
Target Oncol; 2012 Jun; 7(2):91-2. PubMed ID: 22669625
[No Abstract] [Full Text] [Related]
13. New target therapies for patients with neuroendocrine tumors of the pancreas.
Baltogiannis G; Katsios C; Roukos DH
Expert Rev Gastroenterol Hepatol; 2011 Oct; 5(5):563-6. PubMed ID: 21910571
[No Abstract] [Full Text] [Related]
14. Sunitinib paves the way for targeted therapies in neuroendocrine tumors.
Raymond E; Faivre S; Hammel P; Ruszniewski P
Target Oncol; 2009 Dec; 4(4):253-4. PubMed ID: 19911111
[TBL] [Abstract][Full Text] [Related]
15. Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinical trial.
Neychev V; Steinberg SM; Cottle-Delisle C; Merkel R; Nilubol N; Yao J; Meltzer P; Pacak K; Marx S; Kebebew E
BMJ Open; 2015 May; 5(5):e008248. PubMed ID: 25991462
[TBL] [Abstract][Full Text] [Related]
16. Exceptional Responses After Cessation of Therapy With Alkylating Agents for Pancreatic Neuroendocrine Tumors.
Wu YL; Raj N; Reidy-Lagunes D
Pancreas; 2020 Jan; 49(1):e14-e16. PubMed ID: 31856101
[No Abstract] [Full Text] [Related]
17. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
Raymond E; Dahan L; Raoul JL; Bang YJ; Borbath I; Lombard-Bohas C; Valle J; Metrakos P; Smith D; Vinik A; Chen JS; Hörsch D; Hammel P; Wiedenmann B; Van Cutsem E; Patyna S; Lu DR; Blanckmeister C; Chao R; Ruszniewski P
N Engl J Med; 2011 Feb; 364(6):501-13. PubMed ID: 21306237
[TBL] [Abstract][Full Text] [Related]
18. Advances in pancreatic neuroendocrine tumor treatment.
van der Veldt AA; Kleijn SA
N Engl J Med; 2011 May; 364(19):1873; author reply 1873-5. PubMed ID: 21561355
[No Abstract] [Full Text] [Related]
19. Predictive Markers of Response to Everolimus and Sunitinib in Neuroendocrine Tumors.
Martins D; Spada F; Lambrescu I; Rubino M; Cella C; Gibelli B; Grana C; Ribero D; Bertani E; Ravizza D; Bonomo G; Funicelli L; Pisa E; Zerini D; Fazio N;
Target Oncol; 2017 Oct; 12(5):611-622. PubMed ID: 28634872
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxic chemotherapy for pancreatic neuroendocrine tumors.
Okusaka T; Ueno H; Morizane C; Kondo S; Sakamoto Y; Takahashi H; Ohno I; Shimizu S; Mitsunaga S; Ikeda M
J Hepatobiliary Pancreat Sci; 2015 Aug; 22(8):628-33. PubMed ID: 25940377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
